ClinicalTrials.gg
RecruitingNCT07164105Updated Apr 20, 2026

LIFU Mechanisms for PTSD in Healthcare Workers

An interventional study of Low intensity focused ultrasound and Sham modulation in PTSD and Trauma-related Symptoms, sponsored by Laureate Institute for Brain Research, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Laureate Institute for Brain Research, Inc. · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Planned enrollment
736th of 1,491
66 · median 65
Started
2025
with 85 others
No phase
1,012 of 1,664
234 open now
Primary completion
2028-08
later than 296 of 402 live
Registered
1,553rd of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 736th largest by planned enrollment of the 1,491 interventional ones that give a count, is one of 86 that started in 2025, is one of 1,012 with no phase, reaches primary completion later than 296 of the 402 other live ones, and was the 1,553rd registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether low-intensity focused ultrasound (LIFU) of the ventral anterior cingulate cortex (vACC) can normalize dysfunctional brain activation patterns and behaviors in frontline healthcare workers with post-traumatic stress disorder. The main questions it aims to answer are:

  • Does LIFU of the vACC effect activity and connectivity of the vACC and amygdala?
  • Does LIFU of the vACC reduce post-traumatic stress symptoms? Researchers will compare LIFU to sham modulation to see if LIFU modulates activity of vACC-amygdala circuitry and affects threat sensitivity and emotion regulation.

Participants will:

  • Complete two fMRI sessions (before and after LIFU)
  • Receive a single session of LIFU or sham modulation of the vACC
  • Wear a wearable device that tracks sleep and heart rate metrics
Read the detailed description

The study employs a double-blind, randomized, sham-controlled design to evaluate whether low-intensity focused ultrasound (LIFU) targeting the ventral anterior cingulate cortex (vACC) can normalize fronto-limbic circuitry and reduce post-traumatic stress symptomatology in frontline healthcare workers. Sixty-six frontline healthcare professionals aged 18-65 (PCL-5 ≥ 33 or at least partial PTSD on the MINI) will complete baseline assessments that include structural MRI, resting-state fMRI, and two task-based scans. Concurrently, participants initiate continuous Oura Ring wearable monitoring and daily ecological momentary assessment (EMA) surveys. Subjects will return for active or sham LIFU neuromodulation of the vACC. Before and after LIFU, identical MRI and questionnaire batteries quantify acute neural and behavioral change.

03

Conditions studied

  • PTSD and Trauma-related Symptoms
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults in a frontline healthcare position (e.g. emergency medical services)
  2. Ages 18-65 years
  3. PTSD Checklist for (PCL-5) score ≥ 33 and \< 65, OR at least partial PTSD as measured by the MINI
  4. English proficiency as evaluated by language ability during screening

Exclusion criteria

Exclusion Criteria:

  1. Neurological disorders
  2. diagnosis of psychotic disorders, eating disorder, obsessive-compulsive disorder, moderate to severe alcohol or substance use disorder within the past year, bipolar disorder, or major depressive disorder with psychosis
  3. Suicidal intent or plan (as measured by Suicide-Risk-Assessment-C-SSRS "Yes" answers to items 3, 4 or 5 of Suicidal Ideation-Past 1 month section, or any "Yes" answer to any of the items of Suicidal Behavior-Past 3 months section), or any suicide attempt in the last 3 months.
  4. History of severe traumatic brain injury (as indicated by score ≥ 3 on the Tulsa Head Injury Screen) or of skull fractures
  5. to MRI as determined by the MR Environment Screening
  6. Pregnancy, determined by urine pregnancy test administered prior to every MRI scanning procedure
  7. Evidence of inability to comply with study procedures based on experimenter judgement.
  8. Change in the dose or prescription of a medication within the 6 weeks before enrolling in the study that could affect brain functioning, e.g., anxiolytics, antipsychotics, antidepressants, benzodiazepines, or mood stabilizers.
  9. Non-correctable vision or hearing problems
  10. Unstable medical diagnoses
  11. Any structural abnormalities in the LIFU target region on screening brain MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Low intensity focused ultrasound (LIFU)

    LIFU of the ventral anterior cingulate cortex

    Device: Low intensity focused ultrasound

  • Sham comparator
    Sham

    Sham neuromodulation (Sorbothane membrane over ultrasound probe)

    Device: Sham modulation

Interventions

  • DeviceLow intensity focused ultrasound

    Low intensity focused ultrasound neuromodulation of the ventral anterior cingulate cortex

    Also known as: LIFU

  • DeviceSham modulation

    Low intensity focused ultrasound with a Sorbothane membrane cover to prevent acoustic energy transmission

06

What researchers measure

Primary outcomes

  1. LIFU target engagement

    Percent BOLD signal change in vACC and amygdala regions of interest

    Time frame: Study day 1 to day 7 (plus or minus 3 days)

  2. Behavioral changes

    Change in reaction time (ms) and error rate (percentage of correct answers) on emotional conflict task; difference between optimal and observed flight initiation distance.

    Time frame: Day 0 to Day 7 (plus or minus 3 days)

Secondary outcomes

  1. LIFU effects on physiology

    Change in heart rate variability (ms), change in resting heart rate (beats per minute), change in %REM sleep (minutes), change in %deep sleep (minutes) as measured by Oura Ring

    Time frame: Day 0 to day 14 (plus or minus 6 days)

  2. LIFU effects on PTSD symptoms

    Change in PCL-5 score

    Time frame: Dy 0 to day 14 (plus or minus 6)

  3. fMRI-heart rate variability correlation

    Correlations between vACC/amygdala BOLD signal extracted beta-weights and heart rate variability (ms) as measured by Oura Ring

    Time frame: Day 0 to day 14 (plus or minus 6)

  4. fMRI-resting heart rate correlation

    Correlations between vACC/amygdala BOLD signal extracted beta-weights and resting heart rate (beats per minute) as measured by Oura ring

    Time frame: Day 0 to day 14 (plus or minus 6)

  5. fMRI-REM sleep correlation

    Correlations between vACC/amygdala BOLD signal extracted beta-weights and %REM sleep (minutes) as measured by Oura ring

    Time frame: Day 0 to day 14 (plus or minus 6)

  6. fMRI-deep sleep correlation

    Correlations between vACC/amygdala BOLD signal extracted beta-weights and %deep sleep (minutes) as measured by Oura ring

    Time frame: Day 0 to day 14 (plus or minus 6)

  7. fMRI-PTSD Symptom Correlation

    Correlations between vACC/amygdala BOLD signal extracted beta-weights and PCL-5 score.

    Time frame: Day 0 to day 14 (plus or minus 6)

  8. fMRI-Emotion Regulation Correlation

    Correlations between vACC/amygdala BOLD signal extracted beta-weights and Cognitive-Emotion Regulation Questionnaire Score.

    Time frame: Day 0 to day 14 (plus or minus 6)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2028, 32 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 32 months is close to that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 9, 2025
StartActual
Dec 29, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07164105
Lead sponsor
Laureate Institute for Brain Research, Inc.
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Dec 29, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Apr 20, 2026

Study contacts

Adrienne Taren, MD, PhD
Contact
ataren@laureateinstitute.org
918-340-4116

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion